本文選題：解毒化瘀顆粒 + 慢加急性肝衰竭�。� 參考：《廣西中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的:通過隨機對照臨床研究,觀察解毒化瘀顆粒治療慢加急性肝衰竭的臨床療效,為解毒化瘀顆�？山档吐蛹毙愿嗡ソ呋颊叩乃劳雎侍峁┭C醫(yī)學(xué)證據(jù)。方法:采用隨機、對照臨床研究,將符合納入標準的46例慢加急性肝衰竭患者隨機分為治療組與對照組,治療組在西醫(yī)綜合治療基礎(chǔ)上加用解毒化瘀顆粒,對照組予西醫(yī)綜合治療。觀察的終點為8周。通過觀察慢加急性肝衰竭患者死亡率、肝功能、凝血功能及中醫(yī)證候評分等,評估解毒化瘀顆粒對慢加急性肝衰竭的臨床療效。結(jié)果:研究結(jié)果顯示,解毒化瘀顆粒聯(lián)合西醫(yī)綜合治療的中西醫(yī)結(jié)合方案能顯著降低患者死亡率,并優(yōu)于單純西醫(yī)綜合治療組(P0.05)。治療組和對照組總有效率分別為69.57%和39.13%,差異有統(tǒng)計學(xué)意義(P0.05)。治療后第4、第8周,各時間點兩組患者TBiL對比差異均有統(tǒng)計學(xué)意義(P0.05),治療組優(yōu)于對照組。治療后第4周兩組患者PTA對比差異有統(tǒng)計學(xué)意義(P0.05),治療組對于凝血功能的改善優(yōu)于對照組,治療后第8周,兩組患者PTA對比差異無統(tǒng)計學(xué)意義(P0.05)。治療8周后,兩組患者中醫(yī)證候評分均顯著下降,治療組與對照組各時間點相比差異均有統(tǒng)計學(xué)意義(P0.05),治療組改善中醫(yī)證候評分優(yōu)于對照組。結(jié)論:應(yīng)用解毒化瘀顆粒聯(lián)合西醫(yī)綜合治療方案,可顯著改善慢加急性肝衰竭患者短期預(yù)后(8周),并能降低患者死亡率,提高肝功能復(fù)常率,促進凝血機制的恢復(fù),總體臨床療效優(yōu)于單純西醫(yī)綜合治療。
[Abstract]:Objective: to observe the clinical efficacy of jiedu Huayu granule in the treatment of chronic and acute liver failure by randomized controlled clinical study, and to provide evidence-based medical evidence for reducing the mortality rate of patients with chronic and acute liver failure. Methods: 46 patients with chronic and acute hepatic failure were randomly divided into treatment group and control group. The treatment group was treated with jiedu Huayu granule on the basis of comprehensive western medicine. The control group was treated with comprehensive western medicine. The end point of observation was 8 weeks. By observing the mortality rate, liver function, coagulation function and TCM syndrome score of patients with chronic and acute liver failure, the clinical efficacy of jiedu Huayu granule in treating chronic and acute liver failure was evaluated. Results: the results showed that the combined treatment of jiedu Huayu granule and western medicine could significantly reduce the mortality rate of patients, and was better than that of the simple integrated treatment group of western medicine (P0.05). The total effective rates of the treatment group and the control group were 69.57% and 39.13%, respectively. The difference was statistically significant (P 0.05). There were significant differences in TBiL between the two groups at the 4th and 8th week after treatment. The treatment group was superior to the control group. There was significant difference in PTA between the two groups at the 4th week after treatment. The improvement of coagulation function in the treatment group was better than that in the control group. At the 8th week after treatment, there was no significant difference in PTA contrast between the two groups (P 0.05). After 8 weeks of treatment, the TCM syndrome scores of the two groups were significantly decreased, the difference between the treatment group and the control group at each time point was statistically significant (P 0.05), and the improvement of TCM syndrome score in the treatment group was better than that in the control group. Conclusion: the combined treatment of jiedu Huayu granule and western medicine can significantly improve the short-term prognosis of patients with chronic and acute liver failure for 8 weeks, reduce the mortality of patients, increase the recovery rate of liver function, and promote the recovery of coagulation mechanism. The overall clinical efficacy is superior to that of western medicine alone.
【學(xué)位授予單位】：廣西中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R259

【相似文獻】

相關(guān)期刊論文 前10條

1 魚康康;李寧;施光峰;;在爭議中邁步向前:慢加急性肝衰竭研究進展[J];肝臟;2014年03期

2 ;慢加急性肝衰竭的8項定義[J];現(xiàn)代醫(yī)院;2008年05期

3 朱愛紅;丁葦;;恩替卡韋治療慢加急性肝衰竭的臨床觀察[J];齊齊哈爾醫(yī)學(xué)院學(xué)報;2009年14期

4 蔣偉;諶寧生;;諶寧生教授治療慢加急性肝衰竭的經(jīng)驗[J];中西醫(yī)結(jié)合肝病雜志;2010年06期

5 張晶;;慢加急性肝衰竭臨床診斷與治療研究熱點[J];山東醫(yī)藥;2011年16期

6 劉明;鄧國宏;譚順;劉洪利;孫小雯;譚文婷;毛青;;慢加急性肝衰竭前期臨床常規(guī)預(yù)警指標研究[J];第三軍醫(yī)大學(xué)學(xué)報;2012年08期

7 劉芳蓉;葉永安;;慢加急性肝衰竭的診治體會[J];中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志;2012年05期

8 劉曉燕;陳婧;王曉霞;胡瑾華;;3233例急性、亞急性、慢加急性肝衰竭病因特點分析[J];臨床醫(yī)學(xué)工程;2012年05期

9 李廣明;;核苷(酸)類似物治療慢加急性肝衰竭臨床研究[J];求醫(yī)問藥(下半月);2012年06期

10 劉明;張緒清;毛青;;慢加急性肝衰竭前期的概念及預(yù)警模型[J];臨床肝膽病雜志;2012年10期

相關(guān)會議論文 前10條

1 陳姝;蘭英華;姜立勝;李用國;;核苷類似物應(yīng)用與慢加急性肝衰竭發(fā)生及預(yù)后相關(guān)性分析[A];中華醫(yī)學(xué)會第十六次全國病毒性肝炎及肝病學(xué)術(shù)會議論文匯編[C];2013年

2 胡瑾華;劉曉燕;王慧芬;陳菊梅;;1977例急性、亞急性、慢加急性肝衰竭病因分析[A];第一屆全國疑難重型肝病大會、第四屆全國人工肝及血液凈化學(xué)術(shù)年會論文集[C];2008年

3 王魯文;王立坤;陳輝;李汛;龔作炯;;丙酮酸乙酯對實驗性慢加急性肝衰竭大鼠的保護作用[A];全國第4屆中西醫(yī)結(jié)合傳染病學(xué)術(shù)會議論文匯編[C];2012年

4 劉倩;李媛;白佳;許婷;趙雪琪;郝友華;丁紅暉;朱帆;趙西平;;慢加急性肝衰竭患者外周血NK細胞頻率與功能的變化[A];中華醫(yī)學(xué)會第十六次全國病毒性肝炎及肝病學(xué)術(shù)會議論文匯編[C];2013年

5 王魯文;王立坤;陳輝;李汛;龔作炯;;丙酮酸乙酯對實驗性慢加急性肝衰竭大鼠的保護作用[A];中華醫(yī)學(xué)會第十六次全國病毒性肝炎及肝病學(xué)術(shù)會議論文匯編[C];2013年

6 譚善忠;張e，

本文編號：2029582